

Market insights summary


Global Biosurgical Agent market

What's trending and new

01. Strong adoption of ORC-based hemostats

The ease-of-use, high cost-effectiveness, reduced patient readmission rates, and rising physician awareness of ORC-based hemostats will continue to drive growth in the market.


Global biosurgical agent market, by product type, USD M



02. Orthopedic specialty is the biggest contributor to the biosurgical agent market

Orthopedic procedures have the highest penetration rate of biosurgical agents, primarily due to the rising demand for minimally invasive surgeries. In 2023, orthopedic procedures accounted for approximately 39% of total biosurgical agent units sold, and this trend is expected to continue throughout the forecast period.

Biosurgical Agent Revenues, by Specialty, 2023



Access more insights and data in the [report](#).
[Speak to our team](#) to see how we can power your innovation.

2023 Global biosurgical agent market snapshot

(Includes US, Europe, Latin America, Japan, Asia Pacific)


\$4.3 B

Market revenue

2.7%

CAGR ('19-'33)

Biosurgical Agent Revenues, by Region, USD M, 2023



Top competitors in the biosurgical agent market, 2023

Ethicon

In 2023, Ethicon was the leading competitor in the biosurgical agent market, owing to its broad product portfolio across multiple segments and its strong presence in the surgical hemostat segment with SURGICEL and SURGIFLO.

Baxter

In 2023, Baxter ranked as the second-leading competitor in the biosurgical agent market, leveraging a strong presence across all segments. It holds a leading position in the gelatin-thrombin combination hemostat segment, driven by the success of its FLOSEAL and RECOTHROM products. The FDA approval of Baxter's PerClot in 2023 further expanded its market share in the polysaccharide-based surgical hemostat segment.